Australia is the first nation to license the medical use of the psychedelic drugs MDMA for post-traumatic stress disorder and psilocybin for depression (Nature 619, 227–228; 2023). There is a danger that this approval could encourage unsupervised uptake worldwide.
Table of Contents
Research of all three authors is financed by the German Federal Ministry of Education and Research (01GP2214). D.R. is a founding member and honorary board chair of MAPS Deutschland. The Charité has received research grants from COMPASS Pathways and MAPS Europe.